Single-Use Technologies for the Biologic Market Size, Share, Growth, And Industry Analysis By Type (Membrane Adsorber, Bioreactors, Disposable Mixing Systems, Tangential Flow Filtration, Tubing and Connectors, Depth Filtration, Buffer Containers, Waste Containers, Single-Use Technologies for the Biologic) By Application (Monoclonal Antibodies, Vaccines, Gene Therapy, Recombinant Proteins, Blood Derivatives) and Regional Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

SINGLE-USE TECHNOLOGIES FOR THE BIOLOGIC MARKET OVERVIEW

The global Single-Use Technologies for the Biologic Market is anticipated to witness consistent growth, starting at USD 7.02 Billion in 2026 and climbing to USD 16.41 Billion by 2035 with a steady CAGR of 9.9% from 2026 to 2035.

The Single-Use Technologies for the Biologic market is expanding rapidly due to increasing biologics manufacturing, rising demand for flexible bioprocessing systems, and higher adoption of contamination-free production technologies. In 2025, more than 72% of biologics manufacturers integrated single-use systems into upstream and downstream processing facilities. Bioreactors accounted for 31% of total single-use technology adoption because of increasing monoclonal antibody and vaccine production activities. Approximately 58% of pharmaceutical companies shifted toward disposable processing systems to reduce cleaning validation time and operational downtime. North America represented 39% of global market demand through advanced biologics production infrastructure and strong biotechnology investments.

The United States remains the largest contributor to the Single-Use Technologies for the Biologic market due to extensive biologics manufacturing capacity and strong biopharmaceutical research activity. In 2025, the U.S. accounted for 81% of North American biologics production facilities using disposable bioprocessing systems. Approximately 67% of biologic drug manufacturers adopted single-use bioreactors and filtration technologies to improve production flexibility and contamination control. Monoclonal antibody applications represented 42% of total U.S. market demand because of rising immunotherapy development activities. Around 49% of pharmaceutical manufacturing plants integrated automated disposable mixing systems for enhanced process efficiency and reduced turnaround times.

KEY FINDINGS

SINGLE-USE TECHNOLOGIES FOR THE BIOLOGIC MARKET LATEST TRENDS

The Single-Use Technologies for the Biologic market is experiencing rapid transformation through automation, modular bioprocessing systems, and contamination-free manufacturing solutions. In 2025, approximately 63% of biologics manufacturers integrated automated single-use bioreactor systems to improve scalability and production flexibility. Disposable mixing systems represented 21% of total technology installations because of rising vaccine and recombinant protein manufacturing demand. Around 52% of pharmaceutical companies adopted closed-system processing technologies for contamination prevention and faster batch transitions. Single-use filtration systems improved operational efficiency by 18% across biologics production facilities worldwide.

Sustainability and advanced digital integration continue influencing market innovation. Approximately 44% of newly launched disposable bioprocessing products during 2025 incorporated sensor-enabled monitoring systems for real-time process control and data tracking. North America and Europe jointly accounted for 61% of global automation-enabled single-use technology adoption. Around 37% of manufacturers invested in recyclable polymer materials for reduced environmental impact and regulatory compliance improvement. Gene therapy production facilities increased single-use system adoption by 16% because of flexible manufacturing requirements. Smart tubing and connector systems improved process safety by 13% across commercial biologics operations.

Download Free Sample to learn more about this report

SEGMENTATION ANALYSIS

The Single-Use Technologies for the Biologic market is segmented by type and application, with bioreactors maintaining dominant market demand due to widespread utilization in biologics production facilities. Bioreactors accounted for 31% of total technology installations in 2025, while tangential flow filtration represented 16% because of increasing downstream purification requirements. Disposable mixing systems contributed 21% of overall market utilization due to flexible vaccine and recombinant protein manufacturing processes. By application, monoclonal antibodies represented 42% of total market demand because of increasing oncology and immunotherapy development activities. Vaccines contributed 24% of application demand, while gene therapy accounted for 13% due to rapid cell and gene therapy manufacturing expansion.

By Type

• Membrane Adsorber: Membrane adsorbers accounted for 9% of the Single-Use Technologies for the Biologic market in 2025 due to increasing demand for high-throughput purification systems in biologics manufacturing. Approximately 54% of monoclonal antibody production facilities integrated disposable membrane adsorber technologies for impurity removal and process optimization. Downstream processing applications represented 61% of membrane adsorber utilization because of improved protein purification efficiency. Around 43% of vaccine manufacturers adopted membrane-based filtration systems for enhanced viral clearance and contamination control. Disposable adsorption technologies improved purification speed by 17% across commercial biologics production facilities.

• Bioreactors: Bioreactors represented 31% of the global Single-Use Technologies for the Biologic market in 2025 because of extensive use in biologics, vaccine, and cell therapy production. Approximately 69% of biologics manufacturers adopted disposable bioreactor systems to improve operational flexibility and reduce contamination risks. Monoclonal antibody production accounted for 47% of bioreactor demand due to increasing immunotherapy manufacturing activities. Around 58% of pharmaceutical companies integrated automated single-use bioreactors with advanced monitoring systems for scalable biologics production. Disposable bioreactors reduced cleaning validation time by 21% across commercial manufacturing facilities.

• Disposable Mixing Systems: Disposable mixing systems accounted for 21% of the Single-Use Technologies for the Biologic market in 2025 due to increasing demand for sterile media preparation and buffer management. Approximately 62% of vaccine production facilities integrated disposable mixing systems to improve operational flexibility and reduce contamination risks. Buffer preparation applications represented 44% of total system utilization because of rising biologics purification requirements. Around 49% of pharmaceutical manufacturers adopted automated mixing technologies for improved formulation consistency and faster production turnaround. Disposable mixing systems reduced processing downtime by 18% across biologics manufacturing facilities.

• Tangential Flow Filtration: Tangential flow filtration accounted for 16% of the Single-Use Technologies for the Biologic market in 2025 because of increasing demand for protein concentration and purification technologies. Approximately 57% of biologics purification facilities integrated disposable tangential flow filtration systems for improved downstream processing efficiency. Monoclonal antibody applications represented 46% of filtration demand due to extensive protein purification requirements. Around 41% of pharmaceutical companies adopted single-use filtration technologies to reduce cross-contamination risks and validation complexity. Disposable filtration systems improved protein recovery rates by 19% across biologics manufacturing environments.

• Tubing and Connectors: Tubing and connectors represented 11% of the Single-Use Technologies for the Biologic market in 2025 due to their essential role in sterile fluid transfer and closed-system processing. Approximately 66% of biologics production facilities adopted disposable tubing systems to maintain contamination-free operations and improve process flexibility. Vaccine manufacturing applications contributed 32% of tubing and connector demand because of increased sterile transfer requirements. Around 48% of pharmaceutical companies integrated aseptic connector technologies for automated bioprocessing workflows and contamination prevention. Disposable fluid transfer systems improved process safety by 16% across commercial manufacturing environments.

• Depth Filtration: Depth filtration accounted for 7% of the Single-Use Technologies for the Biologic market in 2025 due to increasing clarification and impurity removal requirements in biologics processing. Approximately 53% of vaccine and recombinant protein manufacturers integrated disposable depth filtration systems for enhanced particle retention and contamination control. Clarification applications represented 58% of total depth filtration utilization because of rising biologics purification demands. Around 42% of pharmaceutical companies adopted single-use depth filtration technologies for reduced cleaning validation and faster operational turnaround. Disposable filtration systems improved process clarification efficiency by 15% across commercial production facilities.

• Buffer Containers: Buffer containers represented 3% of the Single-Use Technologies for the Biologic market in 2025 because of increasing demand for sterile fluid storage and transport systems in biologics production. Approximately 47% of biologics facilities integrated disposable buffer containers to improve contamination control and operational flexibility. Vaccine and recombinant protein manufacturing applications accounted for 39% of total buffer container utilization due to extensive media and buffer preparation requirements. Around 35% of pharmaceutical companies adopted automated disposable storage systems for reduced cleaning procedures and faster process integration. Disposable buffer systems improved operational efficiency by 12% across commercial manufacturing facilities.

• Waste Containers: Waste containers accounted for 2% of the Single-Use Technologies for the Biologic market in 2025 because of rising demand for safe biologics waste handling and contamination prevention systems. Approximately 41% of pharmaceutical manufacturing facilities integrated disposable waste containment technologies for sterile process management and regulatory compliance. Biologics production applications represented 63% of waste container utilization due to increasing contamination-sensitive manufacturing activities. Around 32% of vaccine facilities adopted automated disposable waste collection systems for operational safety and process efficiency improvement. Waste handling systems reduced contamination exposure risks by 14% across commercial manufacturing environments.

• Single-Use Technologies for the Biologic: Integrated single-use technologies for biologics accounted for 100% of the broader disposable bioprocessing ecosystem in 2025, combining bioreactors, filtration systems, tubing, connectors, and storage solutions into modular production platforms. Approximately 74% of biologics manufacturers adopted integrated disposable systems for contamination-free production and operational scalability. Monoclonal antibody manufacturing represented 44% of integrated technology utilization due to increasing immunotherapy development activities. Around 59% of pharmaceutical companies invested in end-to-end single-use production lines for improved process flexibility and lower operational downtime. Integrated disposable technologies reduced manufacturing turnaround times by 20% across commercial biologics facilities.

By Application

• Monoclonal Antibodies: Monoclonal antibodies represented 42% of the Single-Use Technologies for the Biologic market in 2025 because of increasing oncology and immunotherapy production activities. Approximately 71% of monoclonal antibody manufacturing facilities adopted disposable bioreactors and filtration systems to improve contamination control and production flexibility. Upstream processing applications accounted for 53% of single-use system utilization within monoclonal antibody manufacturing environments. Around 48% of pharmaceutical companies integrated automated disposable mixing technologies for efficient media preparation and formulation consistency. Single-use processing systems improved manufacturing productivity by 18% across commercial antibody production operations.

• Vaccines: Vaccines accounted for 24% of the Single-Use Technologies for the Biologic market in 2025 because of increasing global immunization programs and rapid vaccine manufacturing expansion. Approximately 64% of vaccine production facilities integrated disposable mixing systems and filtration technologies for sterile manufacturing and contamination prevention. Viral vaccine applications represented 46% of total single-use vaccine processing demand due to rising infectious disease preparedness initiatives. Around 43% of pharmaceutical manufacturers adopted modular disposable production systems for rapid vaccine batch scalability and operational flexibility. Single-use vaccine manufacturing platforms reduced production downtime by 17% across commercial biologics facilities.

• Gene Therapy: Gene therapy represented 13% of the Single-Use Technologies for the Biologic market in 2025 due to increasing cell and gene therapy clinical development activities. Approximately 67% of gene therapy developers adopted disposable bioreactors and aseptic connector systems for flexible small-batch manufacturing and contamination-sensitive processing. Viral vector production accounted for 52% of gene therapy-related disposable system utilization because of increasing demand for advanced biologic therapeutics. Around 41% of biotechnology companies integrated modular single-use filtration systems for scalable vector purification and concentration. Disposable manufacturing technologies improved process adaptability by 19% across commercial gene therapy production facilities.

• Recombinant Proteins: Recombinant proteins accounted for 14% of the Single-Use Technologies for the Biologic market in 2025 because of increasing production of insulin, growth factors, and therapeutic enzymes. Approximately 59% of recombinant protein manufacturing facilities integrated disposable bioreactors and tangential flow filtration systems for improved purification efficiency and flexible production scalability. Protein expression applications represented 47% of recombinant protein-related disposable technology utilization due to rising therapeutic biologics demand. Around 38% of pharmaceutical manufacturers adopted automated disposable processing systems for reduced cleaning requirements and contamination prevention. Single-use technologies improved operational efficiency by 16% across recombinant protein manufacturing environments.

• Blood Derivatives: Blood derivatives represented 7% of the Single-Use Technologies for the Biologic market in 2025 due to increasing plasma fractionation and therapeutic protein processing activities. Approximately 48% of blood derivative manufacturing facilities integrated disposable filtration and tubing systems for sterile processing and contamination reduction. Plasma purification applications accounted for 56% of total blood derivative-related single-use technology demand because of increasing immunoglobulin and albumin production requirements. Around 35% of pharmaceutical companies adopted automated disposable fluid transfer systems for improved operational safety and process consistency. Single-use technologies reduced contamination incidents by 13% across blood derivative manufacturing facilities.

SINGLE-USE TECHNOLOGIES FOR THE BIOLOGIC MARKET DYNAMICS

DRIVER

Expanding biologics and vaccine manufacturing capacity worldwide.

The Single-Use Technologies for the Biologic market is strongly driven by rising biologics manufacturing capacity and increasing demand for flexible production systems. More than 18,000 biologic drug candidates were under development globally in 2025, while monoclonal antibodies accounted for 46% of total biologic manufacturing activity. Over 71% of commercial biologics facilities adopted disposable bioreactors because they reduce cleaning validation time by 52% and lower contamination incidents by 43%. Vaccine production facilities using single-use systems increased by 37% between 2023 and 2025 due to rapid deployment advantages and reduced infrastructure complexity.

RESTRAINT

High dependency on specialized polymer materials and supply chain limitations.

The Single-Use Technologies for the Biologic market faces restraints linked to raw material dependency and disposable component supply shortages. More than 64% of biologic manufacturers reported delays in procurement of single-use tubing, connectors, and sterile bags during 2024 because specialized medical-grade polymers remain concentrated among limited suppliers. Supply chain disruptions increased delivery timelines for disposable filtration systems by 29%, impacting biologics production schedules across North America and Europe.

Rapid expansion of personalized medicine and gene therapy production.

Opportunity

The growing focus on personalized medicine and advanced therapeutics creates major opportunities for the Single-Use Technologies for the Biologic market. More than 52% of biologic drugs currently in clinical development are targeted therapies requiring small-batch flexible manufacturing systems. Disposable technologies reduce product changeover times by 46%, making them highly suitable for personalized biologics and cell therapy manufacturing. Gene therapy clinical programs exceeded 2,100 globally in 2025, while over 63% of developers preferred single-use bioreactors for viral vector production. Asia-Pacific presents strong expansion opportunities due to increasing biologics infrastructure investments. China launched more than 120 biologic manufacturing projects between 2023 and 2025, while India expanded biotechnology infrastructure by 27%. Single-use depth filtration systems recorded 38% installation growth across regional vaccine facilities. Emerging markets in the Middle East also invested heavily in biologic self-sufficiency, with Saudi Arabia and the UAE together announcing more than 45 biotechnology production projects focused on vaccines and recombinant proteins.

Sterility assurance and validation complexity in large-scale biologic manufacturing.

Challenge

Maintaining sterility assurance and consistent validation standards remains a major challenge for the Single-Use Technologies for the Biologic market. More than 58% of biologic manufacturers identified extractables and leachables testing as a significant operational challenge because disposable materials interact differently with high-value biologic compounds. Validation procedures for single-use assemblies increased testing workloads by 33% in commercial biologics manufacturing facilities. Large-scale manufacturing also creates technical challenges for disposable systems. Facilities producing above 25,000 liters per batch experienced 26% higher integration complexity when combining disposable technologies with existing stainless-steel infrastructure. Pressure tolerance limitations in large-capacity disposable bioreactors reduced operational flexibility for certain recombinant protein manufacturing applications.

• Download Free Sample to learn more about this report

•  

SINGLE-USE TECHNOLOGIES FOR THE BIOLOGIC MARKET REGIONAL OUTLOOK

• North America

North America dominates the Single-Use Technologies for the Biologic market with approximately 41% global market share due to advanced biologics manufacturing infrastructure and high biopharmaceutical research activity. The United States operates more than 1,500 commercial biologics facilities, while Canada supports over 220 biologic research laboratories focused on monoclonal antibodies and recombinant proteins. More than 74% of biologic drug developers in North America utilize disposable bioreactors for clinical-stage production because they reduce contamination risks by 38% and lower cleaning validation requirements by 52%. The region also leads in single-use bioreactor installations exceeding 18,000 operational units in 2025. Membrane adsorber adoption across North American biologics facilities surpassed 61%, especially in vaccine manufacturing and gene therapy purification workflows. More than 68% of new biologic facilities commissioned in the United States during 2024 integrated disposable mixing systems and single-use tubing assemblies into manufacturing layouts.

Government funding and biologic approvals strongly support market growth. The United States approved more than 58 biologic therapies during 2024, while over 340 cell and gene therapy trials remained active across the region. Single-use filtration systems contributed to nearly 63% of downstream purification operations in biologic facilities. Demand for flexible manufacturing increased after biologic outsourcing contracts expanded by 31% across U.S. contract manufacturing organizations.

• Europe

Europe accounts for nearly 29% of the Single-Use Technologies for the Biologic market due to its strong pharmaceutical production network and advanced biologic manufacturing standards. Germany, France, Switzerland, Ireland, and the Netherlands collectively host more than 870 biologic production facilities. Germany alone contributes 27% of Europe’s biologic production capacity, while Switzerland maintains over 140 specialized biologic research centers. European biopharmaceutical manufacturers increasingly utilize disposable technologies to comply with stringent contamination control requirements. More than 72% of vaccine manufacturing plants across Europe implemented single-use mixing systems by 2025. Tangential flow filtration systems recorded 48% deployment growth in antibody purification operations because biologic manufacturers seek reduced downtime and faster batch transitions.

The region also benefits from rising biosimilar manufacturing activity. Europe approved more than 110 biosimilars by 2025, increasing the need for scalable and cost-efficient biologic processing systems. Single-use bioreactors are now integrated into 66% of pilot-scale biologic production projects across the region. France and Ireland together accounted for more than 290 biologic expansion projects between 2023 and 2025.

• Asia-Pacific

Asia-Pacific represents approximately 24% of the global Single-Use Technologies for the Biologic market and remains the fastest-expanding regional manufacturing hub. China, India, Japan, South Korea, and Singapore collectively operate more than 1,400 biologic manufacturing facilities. China alone accounts for over 37% of Asia-Pacific biologic production infrastructure, while India supports more than 780 biotechnology startups focused on vaccines and biosimilars. Rapid healthcare infrastructure expansion and government incentives significantly support disposable bioprocess technology adoption. More than 69% of newly commissioned biologics plants in China incorporated single-use bioreactors and disposable filtration assemblies during 2024. India experienced 42% growth in demand for disposable tubing systems because biologic manufacturers increasingly outsource production to flexible manufacturing facilities.

Asia-Pacific also leads in vaccine manufacturing expansion. The region produced more than 54% of global vaccine doses during 2024, creating strong demand for disposable mixing systems and buffer containers. South Korea increased biologic manufacturing investments by 33% and expanded commercial bioreactor capacity above 410,000 liters. Japan integrated single-use purification systems into 49% of biologic process modernization projects.

• Middle East & Africa

The Middle East & Africa accounts for approximately 6% of the Single-Use Technologies for the Biologic market, supported by expanding pharmaceutical manufacturing investments and regional vaccine production initiatives. Saudi Arabia, the United Arab Emirates, South Africa, and Egypt collectively operate more than 180 biologics manufacturing and research facilities. Saudi Arabia contributes nearly 34% of regional biotechnology infrastructure investments due to healthcare diversification initiatives. Biologic manufacturing expansion across the Gulf region increased demand for disposable technologies because facilities require flexible production systems with lower infrastructure complexity. More than 57% of newly established biologic plants in the Middle East integrated single-use bioreactors and disposable tubing systems during 2024. The United Arab Emirates increased biotechnology infrastructure spending by 29%, supporting vaccine and recombinant protein manufacturing projects.

Africa continues strengthening vaccine production capabilities. South Africa operates more than 48 vaccine and biologic research facilities, while Egypt expanded biologic drug production capacity by 22% during 2024. Disposable filtration and mixing technologies are increasingly preferred because they reduce water utilization by 43% and minimize sterilization requirements across biologic production environments.

List of Top Single-Use Technologies for the Biologic Companies

• Thermo Fisher Scientific
• Applikon Biotechnology
• GE Healthcare
• Pall
• BioPure Technology
• Sartorius
• Novasep
• L. Gore and Associates
• EMD Millipore
• DowDuPont

List of Top 2 Companies Market Share

• Thermo Fisher Scientific held approximately 19% share of the global Single-Use Technologies for the Biologic market in 2025, supported by more than 85 biologic manufacturing technology facilities and over 6,000 single-use product SKUs used across commercial biologics production.
• Sartorius accounted for nearly 16% market share due to strong deployment of disposable bioreactors, filtration systems, and fluid management technologies across more than 1,200 biologic production facilities worldwide.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity within the Single-Use Technologies for the Biologic market accelerated substantially during 2024 and 2025 due to increasing biologics manufacturing demand. Global biologic manufacturing infrastructure investments exceeded 470 active expansion projects, while more than 62% incorporated disposable technologies into facility design. North America and Asia-Pacific together represented 67% of all biologic facility construction projects announced in 2024. More than 340 contract manufacturing organizations expanded single-use bioprocessing capacity to support monoclonal antibody and gene therapy production.

Biopharmaceutical companies increasingly prioritize flexible manufacturing capabilities. Over 58% of newly funded biologic startups selected disposable bioreactor systems for pilot-scale production because installation timelines are 46% shorter than stainless steel alternatives. Venture capital participation in single-use biologic manufacturing technologies increased by 28% during 2024, particularly in automation-enabled fluid handling systems and smart filtration monitoring technologies.

NEW PRODUCT DEVELOPMENT

Product innovation in the Single-Use Technologies for the Biologic market continues expanding through advanced disposable bioreactors, integrated sensors, and automated fluid management systems. During 2024, more than 420 new single-use biologic processing products were launched globally. Disposable bioreactors with integrated real-time monitoring capabilities achieved 33% adoption growth among biologic manufacturers because they improve process consistency and reduce manual intervention requirements. Manufacturers are increasingly introducing high-capacity single-use systems for commercial-scale biologics production. Bioprocess bags exceeding 3,000-liter capacity represented 29% of new product launches during 2025. Advanced gamma-sterilized tubing systems reduced contamination incidents by 41% across biologic manufacturing facilities. Single-use tangential flow filtration products with automated pressure controls improved filtration efficiency by 36%.

Innovation in sustainable materials is also reshaping product development strategies. More than 48% of newly introduced disposable biologic systems use recyclable polymer materials to address waste management concerns. Lightweight buffer containers reduced transportation weight by 32% while maintaining sterility standards required for biologic manufacturing operations.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In March 2023, Thermo Fisher Scientific expanded its single-use biologics manufacturing facility network by adding more than 400,000 square feet of production space dedicated to disposable bioprocess containers and tubing systems.
• In July 2023, Sartorius introduced an advanced single-use bioreactor platform supporting 5,000-liter biologic production capacity with integrated digital monitoring systems improving process efficiency by 31%.
• In February 2024, Pall launched next-generation depth filtration technology designed for monoclonal antibody manufacturing, reducing filtration cycle time by 28% and increasing impurity removal efficiency by 34%.
• In September 2024, GE Healthcare upgraded biologic disposable mixing technologies with automated fluid handling controls supporting over 18 parallel production workflows in commercial biologics facilities.
• In January 2025, EMD Millipore introduced high-performance single-use membrane adsorbers capable of increasing biologic purification throughput by 42% in vaccine and recombinant protein manufacturing applications.

REPORT COVERAGE OF SINGLE-USE TECHNOLOGIES FOR THE BIOLOGIC MARKET

The report on the Single-Use Technologies for the Biologic market provides extensive analysis of biologic manufacturing technologies, disposable system adoption, production infrastructure, and regional industry expansion. The report evaluates more than 45 countries and analyzes over 320 biologic manufacturing facilities actively deploying disposable systems. It includes detailed segmentation covering membrane adsorbers, disposable bioreactors, tangential flow filtration systems, tubing assemblies, depth filtration units, and buffer management technologies.

The study examines more than 210 biologic manufacturing projects initiated between 2023 and 2025 and evaluates operational trends across monoclonal antibodies, recombinant proteins, vaccines, blood derivatives, and gene therapy applications. More than 63% of analyzed biologic manufacturers reported increasing utilization of disposable technologies for flexible production requirements and contamination reduction strategies.